ArticleEuropean urology open science2023
Prediction and Mapping of Intraprostatic Tumor Extent with Artificial Intelligence.
Article in European urology open science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Optimizing prostate cancer treatment with MR-guided focused ultrasound: the role of expanded ablation-to-lesion volume ratio.European radiology · 2026Trial
- Contemporary Evidence for Optimization of Robotic Radical Prostatectomy Outcomes Using Advanced Imaging Techniques.Journal of clinical medicine · 2026Review
- Application and prospect of artificial intelligence in diagnostic imaging of prostate cancer.NPJ digital medicine · 2026Review
- Multimodal artificial intelligence in urologic precision oncology: from algorithm to translational medicine (a systemized narrative review).Frontiers in oncology · 2026Review
- Whole-mount histopathology as spatial ground truth for artificial intelligence in prostate cancer: a structured narrative review of techniques, models, and translational gaps.American journal of clinical and experimental urology · 2026Review
- Focal therapy of prostate cancer: Use of artificial intelligence to define tumour volume and predict treatment outcomes.BJUI compass · 2025Article
- Patients and generative AI: Who owns your diagnosis?BJUI compass · 2024Article
- Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm.BJUI compass · 2024Article
- Evaluation of prostate cancer detection using micro-ultrasound versus MRI through co-registration to whole-mount pathology.Scientific reports · 2024Article
- Artificial Intelligence Improves the Ability of Physicians to Identify Prostate Cancer Extent.The Journal of urology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
Background: Magnetic resonance imaging (MRI) underestimation of prostate cancer extent complicates the definition of focal treatment margins. Objective: To validate focal treatment margins produced by an artificial intelligence (AI) model. Design setting and participants: Testing was conducted retrospectively in an independent dataset of 50 consecutive patients who had radical prostatectomy for intermediate-risk cancer. An AI deep learning model incorporated multimodal imaging and biopsy data to produce three-dimensional cancer estimation maps and margins. AI margins were compared with conventional MRI regions of interest (ROIs), 10-mm margins around ROIs, and hemigland margins. The AI model also furnished predictions of negative surgical margin probability, which were assessed for accuracy. Outcome measurements and statistical analysis: Comparing AI with conventional margins, sensitivity was evaluated using Wilcoxon signed-rank tests and negative margin rates using chi-square tests. Predicted versus observed negative margin probability was assessed using linear regression. Clinically significant prostate cancer (International Society of Urological Pathology grade ≥2) delineated on whole-mount histopathology served as ground truth. Results and limitations: The mean sensitivity for cancer-bearing voxels was higher for AI margins (97%) than for conventional ROIs (37%, Conclusions: The AI model was accurate and effective in an independent test set. This approach could improve and standardize treatment margin definition, potentially reducing cancer recurrence rates. Furthermore, an accurate assessment of negative margin probability could facilitate informed decision-making for patients and physicians. Patient summary: Artificial intelligence was used to predict the extent of tumors in surgically removed prostate specimens. It predicted tumor margins more accurately than conventional methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.